腹腔热灌注化疗联合细胞减灭术对胆囊癌腹膜转移的临床疗效研究

Clinical efficacy of hyperthermic intraperitoneal chemotherapy plus cytoreductive surgery for peritoneal metastasis of gallbladder cancer

    摘要
  • 摘要:
      目的  探讨腹腔热灌注化疗（hyperthermic intraperitoneal chemtheropy，HIPEC）治疗胆囊癌伴腹膜转移患者的临床疗效研究。
      方法  本文回顾性分析海军军医大学东方肝胆外科医院2015年1月至2018年1月收治的84例胆囊癌合并腹膜转移患者，31例患者给予HIPEC联合细胞减灭术（cytoreductive surgery，CRS）+术后1个月全身化疗为研究组，53例给予细胞减灭术+术后1个月全身化疗为对照组，观察比较两组临床疗效及不良反应发生情况。
      结果  研究组中位生存时间为（21.72±2.96）个月，显著长于对照组的（14.93±2.09）个月（P < 0.05）。研究组白细胞减少、血红蛋白减少、血小板减少、胃肠道反应、肝功能损伤和肾功能损伤较对照组无显著性差异（P>0.05）。
      结论  HIPEC治疗进展期胆囊癌临床疗效显著，可延长患者生存时间，不良反应较小，值得推广应用。

     

    Abstract:
      Objective  To investigate the clinical efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) for gallbladder cancer with peritoneal metastasis.
      Methods  Data of 84 patients, who were admitted to Shanghai Eastern Hepatobiliary Surgery Hospital from January 2015 to January 2018, were retrospectively analyzed. Of the total patients, 31 received HIPEC combined with cytoreductive surgery (CRS) plus postoperative systemic chemotherapy one month after surgery as the study group (Group A), and the other 53 underwent CRS plus postoperative systemic chemotherapy one momth after surgery as the control group (Group B). The clinical effects and adverse reactions in the two groups were observed and compared.
      Results  The median survival time in the Group A was (21.72±2.96) months, significantly longer than that of (14.93±2.09) months in Group B (P < 0.05). There were no statistically significant differences in leukopenia, hemoglobinemia, thrombocytopenia, gastrointestinal reaction, liver function injury and renal function injurybetween the two groups (P>0.05).
      Conclusions  HIPEC has significant clinical efficacy for gallbladder cancer with peritoneal metastasis. HIPEC can prolong the survival time and have less side effects.

     

    • HTML全文
    • 参考文献(16)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回